Recruiting
Phase 4

Stellate Ganglion Blockade

Sponsor:

Mayo Clinic

Code:

NCT07570940

Conditions

Coronary Artery Disease

Atrial Fibrillation

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Liposomal bupivacaine

Placebo

Study Details

Brief summary:

The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.

Conditions

Coronary Artery Disease

Atrial Fibrillation

Study ID

NCT07570940

Start date

Sep 29, 2026

Status verified date

Nov, 2026

Completion date

Sep, 2030

Anticipated

Primary completion date

Sep, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible. Robotic CABG procedures are allowed.
  • Cases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if CABG is listed as the primary intervention with other procedures noted as possible additional interventions.
  • Cases will remain eligible if left atrial appendage ligation is concomitantly listed with the CABG.

Exclusion criteria:

  • History of Permanent atrial fibrillation (paroxysmal, persistent or permanent),
  • Mechanical circulatory support implant or explant
  • Heart and/or lung transplant patients
  • Active infection/sepsis
  • Pre-operative anti-arrhythmic use (aside from beta-blockers).
  • MAZE procedures, pulmonary vein isolation or cryotherapy will exclude patients if concomitantly listed with the CABG.
  • Participant has a known allergy to adhesives or hydrogels.
  • Participant has a visible skin injury or broken skin at the location for study device placement.
  • Participant does not have the competency to wear the device for the prescribed patching period.
  • Participant has a neuro-stimulator, as it may disrupt the quality of ECG data.
  • Participants who are pregnant. In accordance with Mayo Clinic's standard cardiac surgery protocol, all women of childbearing potential undergo routine preoperative pregnancy testing. Pregnancy status will therefore be confirmed prior to enrollment. Any participant with a positive pregnancy test will be deemed ineligible and will not be enrolled in the study.
  • Participants who lack the capacity to provide informed consent will not be approached or enrolled in this study.

Study Design

Enrollment

450 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Stellate ganglion block using liposomal bupivacaine

10 mL of liposomal bupivacaine 133 mg (133 mg/10 ml or 1.33%)

placebo comparator: Sham block using saline placebo

10 mL of saline placebo injected in the plane of the right stellate ganglion

Interventions

Liposomal bupivacaine

Patients undergoing isolated coronary artery bypass grafting will receive a stellate ganglion block using liposomal bupivacaine prior to surgery

Placebo

Patients undergoing isolated coronary artery bypass grafting will receive a saline placebo injection to the stellate ganglion prior to surgery

Primary outcome measure

  • Incidence of new-onset postoperative atrial fibrillation (POAF) within one week of isolated coronary artery bypass grafting (CABG) surgery [ Time Frame: 1 week ]

Central Contacts and Locations

Central contacts

Anesthesia Clinical Research Unit (ACRU) Study Team

866-265-9263ripollsanz.juan@mayo.edu

Locations

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

ACRU Study Team

866-265-9263

Principal Investigator:

Juan G. Ripoll Sanz, MD

More Information

Sponsor

Mayo Clinic

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.